MicroRNA-29a contributes to drug-resistance of breast cancer cells to adriamycin through PTEN/AKT/GSK3β signaling pathway

Gene

Volumn 593, Issue 1, 2016, Pages 84-90

  Shen, Hongyu ^a,b   Li, Liangpeng ^c   Yang, Sujin ^a,b   Wang, Dandan ^b   Zhong, Shanliang ^b   Zhao, Jianhua ^b   Tang, Jinhai ^a,b  

^a NANJING MEDICAL UNIVERSITY   (China)

^b JIANGSU CANCER HOSPITAL   (China)

^c NANJING MEDICAL UNIVERSITY   (China)

Author keywords

Breast cancer; Drug resistance; GSK3 ; miR 29a; PTEN

Indexed keywords

DOXORUBICIN; GLYCOGEN SYNTHASE KINASE 3BETA; MICRORNA 29A; PHOSPHATIDYLINOSITOL 3,4,5 TRISPHOSPHATE 3 PHOSPHATASE; PHOSPHOPROTEIN; PROTEIN KINASE B; GSK3B PROTEIN, HUMAN; MICRORNA; MIRN29 MICRORNA, HUMAN; PTEN PROTEIN, HUMAN; RNA;

APOPTOSIS ASSAY; ARTICLE; BREAST CANCER; CANCER RESISTANCE; CONTROLLED STUDY; DOWN REGULATION; ENZYME ACTIVITY; ENZYME PHOSPHORYLATION; FEMALE; GENE EXPRESSION; HUMAN; HUMAN CELL; IN VITRO STUDY; MCF 7 CELL LINE; MTT ASSAY; PRIORITY JOURNAL; QUANTITATIVE ANALYSIS; REAL TIME POLYMERASE CHAIN REACTION; SIGNAL TRANSDUCTION; TUMOR CELL CULTURE; UPREGULATION; WESTERN BLOTTING; APOPTOSIS; BREAST NEOPLASMS; DRUG EFFECTS; DRUG RESISTANCE; GENETICS; MCF-7 CELL LINE; METABOLISM; PATHOLOGY;

APOPTOSIS; BREAST NEOPLASMS; DOXORUBICIN; DRUG RESISTANCE, NEOPLASM; FEMALE; GLYCOGEN SYNTHASE KINASE 3 BETA; HUMANS; MCF-7 CELLS; MICRORNAS; PROTO-ONCOGENE PROTEINS C-AKT; PTEN PHOSPHOHYDROLASE; RNA, NEOPLASM; SIGNAL TRANSDUCTION;

EID: 84990188011     PISSN: 03781119     EISSN: 18790038     Source Type: Journal    
DOI: 10.1016/j.gene.2016.08.016     Document Type: Article

References (31)

1. Chun-Zhi, Z., Lei, H., An-Ling, Z., Yan-Chao, F., Xiao, Y., Guang-Xiu, W., Zhi-Fan, J., Pei-Yu, P., Qing-Yu, Z., Chun-Sheng, K., MicroRNA-221 and microRNA-222 regulate gastric carcinoma cell proliferation and radioresistance by targeting PTEN. BMC Cancer, 10, 2010, 367.
2. Du, J., Wang, L., Li, C., Yang, H., Li, Y., Hu, H., Li, H., Zhang, Z., MicroRNA-221 Targets PTEN to reduce the sensitivity of cervical cancer cells to gefitinib through the PI3K/Akt signaling pathway. Tumour Biol., 2015.
3. Farina, A.K., Bong, Y.S., Feltes, C.M., Byers, S.W., Post-transcriptional regulation of cadherin-11 expression by GSK-3 and beta-catenin in prostate and breast cancer cells. PLoS One, 4, 2009, e4797.
4. Fu, X., Tian, J., Zhang, L., Chen, Y., Hao, Q., Involvement of microRNA-93, a new regulator of PTEN/Akt signaling pathway, in regulation of chemotherapeutic drug cisplatin chemosensitivity in ovarian cancer cells. FEBS Lett. 586 (2012), 1279–1286.
5. Galimov, A., Hartung, A., Trepp, R., Mader, A., Fluck, M., Linke, A., Bluher, M., Christ, E., Krutzfeldt, J., Growth hormone replacement therapy regulates microRNA-29a and targets involved in insulin resistance. J. Mol. Med. (Berl) 93 (2015), 1369–1379.
6. Han, Y.C., Park, C.Y., Bhagat, G., Zhang, J., Wang, Y., Fan, J.B., Liu, M., Zou, Y., Weissman, I.L., Gu, H., microRNA-29a induces aberrant self-renewal capacity in hematopoietic progenitors, biased myeloid development, and acute myeloid leukemia. J. Exp. Med. 207 (2010), 475–489.
7. Hu, Q., Gong, J.-P., Li, J., Zhong, S.-L., Chen, W.-X., Zhang, J.-Y., Ma, T.-F., Ji, H., Lv, M.-M., Zhao, J.-H., Tang, J.-H., Down-regulation of miRNA-452 is associated with Adriamycin-resistance in breast cancer cells. Asian Pac. J. Cancer Prev. 15 (2014), 5137–5142.
8. Kutanzi, K.R., Yurchenko, O.V., Beland, F.A., Checkhun, V.F., Pogribny, I.P., MicroRNA-mediated drug resistance in breast cancer. Clin. Epigenetics 2 (2011), 171–185.
9. Lage, H., Aki-Sener, E., Yalcin, I., High antineoplastic activity of new heterocyclic compounds in cancer cells with resistance against classical DNA topoisomerase II-targeting drugs. Int. J. Cancer 119 (2006), 213–220.
10. Lau, M.T., Klausen, C., Leung, P.C., E-cadherin inhibits tumor cell growth by suppressing PI3K/Akt signaling via beta-catenin-Egr1-mediated PTEN expression. Oncogene 30 (2011), 2753–2766.
11. Liu, P., Cheng, H., Roberts, T.M., Zhao, J.J., Targeting the phosphoinositide 3-kinase pathway in cancer. Nat. Rev. Drug Discov. 8 (2009), 627–644.
12. Majumder, S., Jacob, S.T., Emerging role of microRNAs in drug-resistant breast cancer. Gene Expr. 15 (2011), 141–151.
13. Martin, H.L., Smith, L., Tomlinson, D.C., Multidrug-resistant breast cancer: current perspectives. Breast Cancer (Dove Med Press) 6 (2014), 1–13.
14. Nagano, H., Tomimaru, Y., Eguchi, H., Hama, N., Wada, H., Kawamoto, K., Kobayashi, S., Mori, M., Doki, Y., MicroRNA-29a induces resistance to gemcitabine through the Wnt/beta-catenin signaling pathway in pancreatic cancer cells. Int. J. Oncol. 43 (2013), 1066–1072.
15. O'Driscoll, L., Clynes, M., Biomarkers and multiple drug resistance in breast cancer. Curr. Cancer Drug Targets 6 (2006), 365–384.
16. Ohigashi, T., Mizuno, R., Nakashima, J., Marumo, K., Murai, M., Inhibition of Wnt signaling downregulates Akt activity and induces chemosensitivity in PTEN-mutated prostate cancer cells. Prostate 62 (2005), 61–68.
17. Robertson, N.M., Yigit, M.V., The role of microRNA in resistance to breast cancer therapy. Wiley Interdiscip. Rev. RNA 5 (2014), 823–833.
18. Sarkar, F.H., Li, Y., Wang, Z., Kong, D., Ali, S., Implication of microRNAs in drug resistance for designing novel cancer therapy. Drug Resist. Updat. 13 (2010), 57–66.
19. Torre, L.A., Bray, F., Siegel, R.L., Ferlay, J., Lortet-Tieulent, J., Jemal, A., Global cancer statistics, 2012. CA Cancer J. Clin. 65 (2015), 87–108.
20. Wang, Y.S., Wang, Y.H., Xia, H.P., Zhou, S.W., Schmid-Bindert, G., Zhou, C.C., MicroRNA-214 regulates the acquired resistance to gefitinib via the PTEN/AKT pathway in EGFR-mutant cell lines. Asian Pac. J. Cancer Prev. 13 (2012), 255–260.
21. Wang, J., Wang, Y., Wang, Y., Ma, Y., Lan, Y., Yang, X., J. Biol. Chem. 288 (2013), 10418–10426.
22. Wikman, H., Lamszus, K., Detels, N., Uslar, L., Wrage, M., Benner, C., Hohensee, I., Ylstra, B., Eylmann, K., Zapatka, M., Sauter, G., Kemming, D., Glatzel, M., Muller, V., Westphal, M., Pantel, K., Relevance of PTEN loss in brain metastasis formation in breast cancer patients. Breast Cancer Res., 14, 2012, R49.
23. Xiong, Y., Fang, J.H., Yun, J.P., Yang, J., Zhang, Y., Jia, W.H., Zhuang, S.M., Effects of microRNA-29 on apoptosis, tumorigenicity, and prognosis of hepatocellular carcinoma. Hepatology 51 (2010), 836–845.
24. Yang, W.M., Jeong, H.J., Park, S.Y., Lee, W., Induction of miR-29a by saturated fatty acids impairs insulin signaling and glucose uptake through translational repression of IRS-1 in myocytes. FEBS Lett. 588 (2014), 2170–2176.
25. Yu, D.D., Lv, M.M., Chen, W.X., Zhong, S.L., Zhang, X.H., Chen, L., Ma, T.F., Tang, J.H., Zhao, J.H., Role of miR-155 in drug resistance of breast cancer. Tumour Biol. 36 (2015), 1395–1401.
26. Zeng, C., Wang, R., Li, D., Lin, X.J., Wei, Q.K., Yuan, Y., Wang, Q., Chen, W., Zhuang, S.M., A novel GSK-3 beta-C/EBP alpha-miR-122-insulin-like growth factor 1 receptor regulatory circuitry in human hepatocellular carcinoma. Hepatology 52 (2010), 1702–1712.
27. Zhai, L., Ma, C., Li, W., Yang, S., Liu, Z., miR-143 Suppresses Epithelial-Mesenchymal Transition and Inhibits Tumor Growth of Breast Cancer Through Down-Regulation of ERK5. Mol. Carcinog., 2015.
28. Zhang, J., Han, C., Wu, T., MicroRNA-26a promotes cholangiocarcinoma growth by activating beta-catenin. Gastroenterology 143 (2012), 246–256 (e8).
29. Zhang, X., Zhong, S., Xu, Y., Yu, D., Ma, T., Chen, L., Zhao, Y., Chen, X., Yang, S., Wu, Y., Tang, J., Zhao, J., MicroRNA-3646 contributes to docetaxel resistance in human breast cancer cells by GSK-3beta/beta-catenin signaling pathway. PLoS One, 11, 2016, e0153194.
30. Zhao, X., Lu, Y., Wang, F., Dou, L., Wang, L., Guo, J., Li, J., High glucose reduces hepatic glycogenesis by suppression of microRNA152. Mol. Med. Rep. 10 (2014), 2073–2078.
31. Zhong, S., Li, W., Chen, Z., Xu, J., Zhao, J., MiR-222 and miR-29a contribute to the drug-resistance of breast cancer cells. Gene 531 (2013), 8–14.